Novel EEG Biomarkers in KCNT1 - Peter Galer, PhD

In this powerful seminar, Dr. Peter Galer presents groundbreaking research into the use of quantitative EEG (qEEG) biomarkers to better understand, diagnose, and potentially track treatment response in KCNT1-related epilepsy—a devastating and rare genetic epilepsy.

Dr. Galer, a research scientist at Neumarker and PhD graduate from the University of Pennsylvania, shares his work using machine learning, signal processing, and network neuroscience to identify electrophysiological signatures unique to KCNT1. His findings show how qEEG may be used not only to distinguish KCNT1 from controls and other DEEs (developmental and epileptic encephalopathies), but also to objectively assess disease progression and treatment outcomes.

This seminar includes:

Overview of qEEG methodology and biomarkers (e.g., alpha/delta ratios, power spectral density)

Results from one of the largest pediatric epilepsy EEG cohorts ever analyzed

High-accuracy machine learning classification of KCNT1 vs. other DEEs

Discussion of how qEEG might support clinical trials, especially for fragile populations

Future directions in EEG data sharing, home EEG setups, and precision medicine

If you’re a clinician, researcher, or family affected by KCNT1, this is a must-watch.

Contact Dr. Galer or the KCNT1 Epilepsy Foundation ([email protected]) for collaboration opportunities.

#KCNT1 #Epilepsy #EEG #qEEG #Neuroengineering #MachineLearning #RareDisease #Biomarkers #PrecisionMedicine #GeneticEpilepsy #DevelopmentalEpilepticEncephalopathy #DEEs #ClinicalTrials #Neurology #ChildNeurology #ArtificialIntelligence #NeuroscienceResearch